Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHERYL A HULL

Allopathic & Osteopathic Physicians Dermatology

NPI
1124081849
CMS profile
142103
Location
ROGERS, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$676.63

22 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHERYL A HULL

NPI 1124081849 · CMS profile ID 142103

Allopathic & Osteopathic Physicians / Dermatology

ROGERS, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124081849?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHERYL A HULL, NPI 1124081849, CMS profile ID 142103. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124081849?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CHERYL A HULL, NPI 1124081849, CMS profile ID 142103. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124081849?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CHERYL A HULL, NPI 1124081849, CMS profile ID 142103, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–22 of 22 matching records. This page contains 22 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1124081849?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

22 matching records · $676.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 22 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–22 of 22.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $4.3112/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202080155 CMS
ABBVIE INC. $118.0011/10/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202080153 CMS
Novartis Pharmaceuticals Corporation $17.6711/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200245362 CMS
GENZYME CORPORATION $13.6710/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233384783 CMS
REVANCE THERAPEUTICS, INC. $25.0010/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251165493 CMS
ABBVIE INC. $42.5010/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202080151 CMS
ABBVIE INC. $2.4810/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202080149 CMS
Galderma Laboratories, L.P. $14.1309/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234656628 CMS
ABBVIE INC. $28.9009/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202080147 CMS
ABBVIE INC. $9.7008/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202080145 CMS
ABBVIE INC. $9.9208/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202080143 CMS
Novartis Pharmaceuticals Corporation $19.2806/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200208625 CMS
ABBVIE INC. $18.8106/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202080141 CMS
Galderma Laboratories, L.P. $5.8906/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234656626 CMS
ABBVIE INC. $10.2906/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202080139 CMS
Lilly USA, LLC $121.2006/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186550888 CMS
Galderma Laboratories, L.P. $14.0005/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234656624 CMS
Arcutis Biotherapeutics, Inc. $24.2904/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1252333466 CMS
ABBVIE INC. $7.5704/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202080137 CMS
Lilly USA, LLC $18.7403/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186499763 CMS
Novartis Pharmaceuticals Corporation $16.5602/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200208611 CMS
Galderma Laboratories, L.P. $133.7201/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234656622 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,430.05 27
PY2020 $231.11 11
PY2021 $627.01 26
PY2022 $517.89 25
PY2023 $1,474.67 21
PY2024 $880.69 32
PY2025 $676.63 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $380,038.55 259
PY2024 Principal investigator $408,860.46 382
PY2023 Principal investigator $228,849.11 170
PY2022 Recipient $321.00 1
PY2022 Principal investigator $248,165.36 66
PY2021 Recipient $2,700.00 2
PY2021 Principal investigator $244,500.15 37
PY2020 Recipient $643.47 2
PY2020 Principal investigator $251,307.20 46
PY2019 Recipient $4.75 1
PY2019 Principal investigator $990,287.65 92

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

259 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,260.00 12/19/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564119
Principal investigator 1 Incyte Corporation $6,379.90 12/08/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564200
Principal investigator 1 Incyte Corporation $7.11 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564034
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564057
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564066
Principal investigator 1 Incyte Corporation $33.18 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564072
Principal investigator 1 Incyte Corporation $32.36 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564078
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564098
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564106
Principal investigator 1 Incyte Corporation $49.77 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564111
Principal investigator 1 Incyte Corporation $35.55 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564126
Principal investigator 1 Incyte Corporation $118.26 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564148
Principal investigator 1 Incyte Corporation $68.70 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564153
Principal investigator 1 Incyte Corporation $0.34 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564161
Principal investigator 1 Incyte Corporation $14.22 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564172
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564186
Principal investigator 1 Incyte Corporation $2.12 12/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564208
Principal investigator 1 Incyte Corporation $1,091.70 11/24/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564087
Principal investigator 1 ABBVIE INC. $1,989.00 11/20/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202524874
Principal investigator 1 Incyte Corporation $1,781.00 10/20/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564178
Principal investigator 1 Incyte Corporation $913.60 10/20/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564194
Principal investigator 1 Incyte Corporation $1,349.00 10/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564041
Principal investigator 1 Incyte Corporation $1,349.00 10/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564049
Principal investigator 1 Incyte Corporation $785.40 10/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564133
Principal investigator 1 Incyte Corporation $1,319.00 10/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564140
Principal investigator 1 Organon Llc $2,130.31 09/29/2025 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center. PLLC
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173042818
Principal investigator 1 ABBVIE INC. $1,261.90 09/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202507950
Principal investigator 1 Incyte Corporation $400.00 09/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240563736
Principal investigator 1 Incyte Corporation $1,000.00 09/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240563755
Principal investigator 1 Incyte Corporation $100.00 09/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240563772
Principal investigator 1 Incyte Corporation $1,170.00 09/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240563788
Principal investigator 1 Incyte Corporation $500.00 09/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240563820
Principal investigator 1 Incyte Corporation $80.15 09/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563909
Principal investigator 1 Organon Llc $1,094.38 09/02/2025 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center. PLLC
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173042814
Principal investigator 1 Incyte Corporation $1,172.10 08/20/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563709
Principal investigator 1 Incyte Corporation $1,213.00 08/20/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563717
Principal investigator 1 Incyte Corporation $1,920.00 08/20/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563722
Principal investigator 1 Incyte Corporation $1,213.00 08/20/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563730
Principal investigator 1 Incyte Corporation $1,213.00 08/20/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564025
Principal investigator 1 ABBVIE INC. $1,861.20 08/05/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202501464
Principal investigator 1 Organon Llc $924.38 07/28/2025 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center. PLLC
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173042812
Principal investigator 1 Incyte Corporation $693.00 07/18/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563701
Principal investigator 1 Incyte Corporation $1,349.00 07/18/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563803
Principal investigator 1 Incyte Corporation $1,319.00 07/18/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563811
Principal investigator 1 Incyte Corporation $1,319.00 07/18/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564009
Principal investigator 1 Incyte Corporation $500.00 07/09/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563744
Principal investigator 1 Incyte Corporation $7,000.00 07/09/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563750
Principal investigator 1 Incyte Corporation $1,040.60 07/09/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563765
Principal investigator 1 Incyte Corporation $1,942.00 07/09/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563779
Principal investigator 1 Incyte Corporation $82.20 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563797
Principal investigator 1 Incyte Corporation $82.20 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563829
Principal investigator 1 Incyte Corporation $82.20 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563839
Principal investigator 1 Incyte Corporation $24.66 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563847
Principal investigator 1 Incyte Corporation $24.66 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563852
Principal investigator 1 Incyte Corporation $32.88 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563859
Principal investigator 1 Incyte Corporation $2.48 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563869
Principal investigator 1 Incyte Corporation $24.66 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563875
Principal investigator 1 Incyte Corporation $19.44 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563883
Principal investigator 1 Incyte Corporation $7.29 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563894
Principal investigator 1 Incyte Corporation $74.04 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563901
Principal investigator 1 Incyte Corporation $114.50 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563917
Principal investigator 1 Incyte Corporation $64.72 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563928
Principal investigator 1 Incyte Corporation $123.40 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563932
Principal investigator 1 Incyte Corporation $161.80 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563940
Principal investigator 1 Incyte Corporation $0.93 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563947
Principal investigator 1 Incyte Corporation $98.72 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563957
Principal investigator 1 Incyte Corporation $21.20 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563965
Principal investigator 1 Incyte Corporation $32.88 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563972
Principal investigator 1 Incyte Corporation $32.88 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563980
Principal investigator 1 Incyte Corporation $32.88 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563989
Principal investigator 1 Incyte Corporation $82.20 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563999
Principal investigator 1 Incyte Corporation $24.66 07/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240564015
Principal investigator 1 Organon Llc $871.25 06/30/2025 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center. PLLC
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173042028
Principal investigator 1 Incyte Corporation $341.00 06/25/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563328
Principal investigator 1 Incyte Corporation $1,319.00 06/25/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563349
Principal investigator 1 Incyte Corporation $1,213.00 06/25/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563356
Principal investigator 1 Incyte Corporation $1,920.00 06/25/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563364
Principal investigator 1 Incyte Corporation $1,089.50 06/25/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563588
Principal investigator 1 Incyte Corporation $341.00 06/25/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563656
Principal investigator 1 Incyte Corporation $450.00 06/23/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563281
Principal investigator 1 Incyte Corporation $110.00 06/16/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563387
Principal investigator 1 Incyte Corporation $570.00 06/11/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563371
Principal investigator 1 Incyte Corporation $1,342.00 06/11/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563377
Principal investigator 1 Incyte Corporation $1,942.00 06/11/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563411
Principal investigator 1 Incyte Corporation $1,362.40 06/11/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563663
Principal investigator 1 Incyte Corporation $2,128.00 06/06/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563393
Principal investigator 1 Incyte Corporation $1,385.00 06/06/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563418
Principal investigator 1 Incyte Corporation $1,875.00 06/06/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563436
Principal investigator 1 Incyte Corporation $1,596.00 06/06/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563596
Principal investigator 1 ABBVIE INC. $1,861.20 06/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202489673
Principal investigator 1 Incyte Corporation $4.12 06/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563401
Principal investigator 1 Incyte Corporation $80.15 06/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563441
Principal investigator 1 Incyte Corporation $270.80 06/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563550
Principal investigator 1 Incyte Corporation $3.18 06/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563556
Principal investigator 1 Organon Llc $2,851.75 05/26/2025 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center. PLLC
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173042022
Principal investigator 1 Incyte Corporation $525.20 05/21/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563302
Principal investigator 1 Incyte Corporation $1,920.00 05/21/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563307
Principal investigator 1 Incyte Corporation $1,319.00 05/21/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563563
Principal investigator 1 Incyte Corporation $1,213.00 05/21/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563679
Principal investigator 1 Incyte Corporation $1,213.00 05/21/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563688
Principal investigator 1 ABBVIE INC. $1,144.90 05/06/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202481579
Principal investigator 1 Incyte Corporation $1,372.00 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563320
Principal investigator 1 Incyte Corporation $802.20 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563336
Principal investigator 1 Incyte Corporation $1,342.00 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563341
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563451
Principal investigator 1 Incyte Corporation $48.54 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563504
Principal investigator 1 Incyte Corporation $74.04 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563509
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563516
Principal investigator 1 Incyte Corporation $0.93 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563527
Principal investigator 1 Incyte Corporation $22.90 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563535
Principal investigator 1 Incyte Corporation $14.58 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563545
Principal investigator 1 Incyte Corporation $306.90 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563571
Principal investigator 1 Incyte Corporation $124.54 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563604
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563636
Principal investigator 1 Incyte Corporation $24.66 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563647
Principal investigator 1 Incyte Corporation $1,342.00 05/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563672
Principal investigator 1 Organon Llc $871.25 04/28/2025 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center. PLLC
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173042006
Principal investigator 1 Incyte Corporation $140.00 04/23/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563249
Principal investigator 1 Incyte Corporation $140.00 04/23/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563257
Principal investigator 1 Incyte Corporation $120.00 04/23/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563265
Principal investigator 1 Incyte Corporation $160.00 04/23/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563271
Principal investigator 1 Incyte Corporation $130.00 04/23/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563289
Principal investigator 1 Incyte Corporation $450.00 04/23/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563620
Principal investigator 1 Incyte Corporation $450.00 04/23/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563631
Principal investigator 1 Incyte Corporation $130.00 04/23/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563695
Principal investigator 1 Incyte Corporation $1,613.60 04/09/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563297
Principal investigator 1 Incyte Corporation $1,342.00 04/09/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563312
Principal investigator 1 ABBVIE INC. $1,144.90 04/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202474096
Principal investigator 1 Incyte Corporation $1.03 04/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563428
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563465
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563472
Principal investigator 1 Incyte Corporation $121.90 04/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563482
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563487
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563495
Principal investigator 1 Incyte Corporation $13.39 04/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563580
Principal investigator 1 Incyte Corporation $95.40 04/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563612
Principal investigator 1 Organon Llc $2,197.26 04/01/2025 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center. PLLC
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173042002
Principal investigator 1 Incyte Corporation $1,342.00 03/12/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563032
Principal investigator 1 Incyte Corporation $1,342.00 03/12/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563038
Principal investigator 1 Incyte Corporation $1,342.00 03/12/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563044
Principal investigator 1 Incyte Corporation $805.20 03/12/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563050
Principal investigator 1 ABBVIE INC. $1,514.10 03/06/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202458168
Principal investigator 1 Incyte Corporation $925.70 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562595
Principal investigator 1 Incyte Corporation $1,920.00 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562613
Principal investigator 1 Incyte Corporation $1,781.00 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562627
Principal investigator 1 Incyte Corporation $311.35 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562899
Principal investigator 1 Incyte Corporation $34.35 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562905
Principal investigator 1 Incyte Corporation $49.36 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562911
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562923
Principal investigator 1 Incyte Corporation $21.87 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562929
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562948
Principal investigator 1 Incyte Corporation $311.35 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562959
Principal investigator 1 Incyte Corporation $0.93 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562965
Principal investigator 1 Incyte Corporation $54.76 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562971
Principal investigator 1 Incyte Corporation $12.15 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562978
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562984
Principal investigator 1 Incyte Corporation $1,369.00 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562989
Principal investigator 1 Incyte Corporation $57.25 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562996
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563001
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563007
Principal investigator 1 Incyte Corporation $0.62 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563014
Principal investigator 1 Incyte Corporation $97.08 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563055
Principal investigator 1 Incyte Corporation $11.45 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563068
Principal investigator 1 Incyte Corporation $11.45 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563074
Principal investigator 1 Incyte Corporation $1,319.00 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563117
Principal investigator 1 Incyte Corporation $781.70 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563125
Principal investigator 1 Incyte Corporation $347.10 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563134
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563203
Principal investigator 1 Organon Llc $1,284.56 03/03/2025 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center. PLLC
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173041996
Principal investigator 1 Incyte Corporation $1,481.00 02/10/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562570
Principal investigator 1 Incyte Corporation $1,342.00 02/10/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562576
Principal investigator 1 Incyte Corporation $1,342.00 02/10/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562580
Principal investigator 1 Incyte Corporation $791.30 02/10/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562587
Principal investigator 1 ABBVIE INC. $4,160.10 02/05/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202444307
Principal investigator 1 Novartis Pharmaceuticals Corporation $700.00 02/01/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CENTER FOR PLASTIC SURGERY
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190301339
Principal investigator 1 Organon Llc $3,247.01 01/28/2025 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center. PLLC
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173041980
Principal investigator 1 Incyte Corporation $1,319.00 01/27/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562534
Principal investigator 1 Incyte Corporation $1,781.00 01/27/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562558
Principal investigator 1 Incyte Corporation $1,213.00 01/27/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562563
Principal investigator 1 Incyte Corporation $1,319.00 01/15/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562528
Principal investigator 1 Incyte Corporation $341.00 01/15/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562540
Principal investigator 1 Incyte Corporation $1,213.00 01/15/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562546
Principal investigator 1 Incyte Corporation $805.20 01/15/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562551
Principal investigator 1 Incyte Corporation $1,342.00 01/15/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563218
Principal investigator 1 Incyte Corporation $1,342.00 01/15/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563228
Principal investigator 1 Incyte Corporation $1,342.00 01/15/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563241
Principal investigator 1 Novartis Pharmaceuticals Corporation $50.38 01/15/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CENTER FOR PLASTIC SURGERY
A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1190301337
Principal investigator 1 Eli Lilly and Company $230,765.00 01/10/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187884852
Principal investigator 1 Organon Llc $1,102.88 01/07/2025 Non-covered Recipient Entity
Northwest Arkansas Clinical Trials Center. PLLC
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects No dispute reported 06/30/2026 1173041972
Principal investigator 1 ABBVIE INC. $701.28 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL
M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) No dispute reported 06/30/2026 1202434095
Principal investigator 1 Incyte Corporation $148.40 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562601
Principal investigator 1 Incyte Corporation $143.10 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562607
Principal investigator 1 Incyte Corporation $222.60 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562619
Principal investigator 1 Incyte Corporation $159.00 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562633
Principal investigator 1 Incyte Corporation $275.60 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562640
Principal investigator 1 Incyte Corporation $106.00 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562647
Principal investigator 1 Incyte Corporation $90.10 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562653
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562659
Principal investigator 1 Incyte Corporation $51.03 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562665
Principal investigator 1 Incyte Corporation $84.80 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562672
Principal investigator 1 Incyte Corporation $263.35 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562677
Principal investigator 1 Incyte Corporation $111.30 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562684
Principal investigator 1 Incyte Corporation $58.30 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562690
Principal investigator 1 Incyte Corporation $74.20 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562695
Principal investigator 1 Incyte Corporation $37.66 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562702
Principal investigator 1 Incyte Corporation $53.00 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562708
Principal investigator 1 Incyte Corporation $31.80 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562714
Principal investigator 1 Incyte Corporation $26.50 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562719
Principal investigator 1 Incyte Corporation $145.62 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562726
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562732
Principal investigator 1 Incyte Corporation $4.34 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562738
Principal investigator 1 Incyte Corporation $32.28 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562743
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562749
Principal investigator 1 Incyte Corporation $17.01 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562755
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562762
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562767
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562774
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562780
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562786
Principal investigator 1 Incyte Corporation $16.14 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562791
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562798
Principal investigator 1 Incyte Corporation $249.08 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562803
Principal investigator 1 Incyte Corporation $541.60 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562809
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562815
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562822
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562827
Principal investigator 1 Incyte Corporation $98.72 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562833
Principal investigator 1 Incyte Corporation $9.72 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562839
Principal investigator 1 Incyte Corporation $9.72 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562846
Principal investigator 1 Incyte Corporation $73.98 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562851
Principal investigator 1 Incyte Corporation $73.98 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562857
Principal investigator 1 Incyte Corporation $73.98 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562864
Principal investigator 1 Incyte Corporation $145.62 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562869
Principal investigator 1 Incyte Corporation $171.75 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562875
Principal investigator 1 Incyte Corporation $24.38 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562881
Principal investigator 1 Incyte Corporation $53.56 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562887
Principal investigator 1 Incyte Corporation $135.40 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562893
Principal investigator 1 Incyte Corporation $54.76 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562917
Principal investigator 1 Incyte Corporation $62.27 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562935
Principal investigator 1 Incyte Corporation $98.72 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562941
Principal investigator 1 Incyte Corporation $677.00 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240562953
Principal investigator 1 Incyte Corporation $95.40 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563020
Principal investigator 1 Incyte Corporation $236.52 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563025
Principal investigator 1 Incyte Corporation $26.90 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563062
Principal investigator 1 Incyte Corporation $15.90 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563080
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563085
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563090
Principal investigator 1 Incyte Corporation $24.66 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563095
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563101
Principal investigator 1 Incyte Corporation $21.52 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563108
Principal investigator 1 Incyte Corporation $73.98 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563141
Principal investigator 1 Incyte Corporation $26.50 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563149
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563155
Principal investigator 1 Incyte Corporation $10.76 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563162
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563169
Principal investigator 1 Incyte Corporation $84.80 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563179
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563186
Principal investigator 1 Incyte Corporation $42.40 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563194
Principal investigator 1 Incyte Corporation $74.20 01/02/2025 Non-covered Recipient Entity
NORTHWEST ARKANSAS CLINICAL TRIALS CENTER
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240563209